256 related articles for article (PubMed ID: 20038403)
1. Comparison of iodixanol and ioversol for the prevention of contrast-induced nephropathy in diabetic patients after coronary angiography or angioplasty.
Hernández F; Mora L; García-Tejada J; Velázquez M; Gómez-Blázquez I; Bastante T; Albarrán A; Andreu J; Tascón J
Rev Esp Cardiol; 2009 Dec; 62(12):1373-80. PubMed ID: 20038403
[TBL] [Abstract][Full Text] [Related]
2. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography.
Shin DH; Choi DJ; Youn TJ; Yoon CH; Suh JW; Kim KI; Cho YS; Cho GY; Chae IH; Kim CH
Am J Cardiol; 2011 Jul; 108(2):189-94. PubMed ID: 21545991
[TBL] [Abstract][Full Text] [Related]
3. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention.
Nie B; Cheng WJ; Li YF; Cao Z; Yang Q; Zhao YX; Guo YH; Zhou YJ
Catheter Cardiovasc Interv; 2008 Dec; 72(7):958-65. PubMed ID: 19021282
[TBL] [Abstract][Full Text] [Related]
4. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial.
Rudnick MR; Davidson C; Laskey W; Stafford JL; Sherwin PF;
Am Heart J; 2008 Oct; 156(4):776-82. PubMed ID: 18946896
[TBL] [Abstract][Full Text] [Related]
5. Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI.
Zhang J; Jiang Y; Rui Q; Chen M; Zhang N; Yang H; Zhou Y
Medicine (Baltimore); 2018 May; 97(18):e0617. PubMed ID: 29718868
[TBL] [Abstract][Full Text] [Related]
6. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial.
Jo SH; Youn TJ; Koo BK; Park JS; Kang HJ; Cho YS; Chung WY; Joo GW; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB; Kim HS
J Am Coll Cardiol; 2006 Sep; 48(5):924-30. PubMed ID: 16949481
[TBL] [Abstract][Full Text] [Related]
7. Prediction of contrast-induced nephropathy in diabetic patients undergoing elective cardiac catheterization or PCI: role of volume-to-creatinine clearance ratio and iodine dose-to-creatinine clearance ratio.
Worasuwannarak S; Pornratanarangsi S
J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S29-34. PubMed ID: 20364554
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the nephrotoxic effects of iodixanol versus iohexol in patients with chronic heart failure undergoing coronary angiography or angioplasty.
Song T; Song M; Ge Z; Li Y; Shi P; Sun M
J Interv Cardiol; 2017 Jun; 30(3):281-285. PubMed ID: 28421628
[TBL] [Abstract][Full Text] [Related]
9. Renal tolerability of iopromide and iodixanol in 562 renally impaired patients undergoing cardiac catheterisation: the DIRECT study.
Chen Y; Hu S; Liu Y; Zhao R; Wang L; Fu G; He Q; Su X; Zheng Y; Qi X; Liu H; Wang J; Gao W; Wang M; Liu S; Zheng X; He B; Yang P; Zhou S; Gao C; Qiu C
EuroIntervention; 2012 Nov; 8(7):830-8. PubMed ID: 23045301
[TBL] [Abstract][Full Text] [Related]
10. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study.
Mehran R; Nikolsky E; Kirtane AJ; Caixeta A; Wong SC; Teirstein PS; Downey WE; Batchelor WB; Casterella PJ; Kim YH; Fahy M; Dangas GD
JACC Cardiovasc Interv; 2009 May; 2(5):415-21. PubMed ID: 19463464
[TBL] [Abstract][Full Text] [Related]
11. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients.
Feldkamp T; Baumgart D; Elsner M; Herget-Rosenthal S; Pietruck F; Erbel R; Philipp T; Kribben A
Clin Nephrol; 2006 Nov; 66(5):322-30. PubMed ID: 17140161
[TBL] [Abstract][Full Text] [Related]
12. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the Contrast Media and Nephrotoxicity Following Primary Angioplasty for Acute Myocardial Infarction [CONTRAST-AMI] Trial).
Bolognese L; Falsini G; Schwenke C; Grotti S; Limbruno U; Liistro F; Carrera A; Angioli P; Picchi A; Ducci K; Pierli C
Am J Cardiol; 2012 Jan; 109(1):67-74. PubMed ID: 21943940
[TBL] [Abstract][Full Text] [Related]
13. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial.
Juergens CP; Winter JP; Nguyen-Do P; Lo S; French JK; Hallani H; Fernandes C; Jepson N; Leung DY
Intern Med J; 2009 Jan; 39(1):25-31. PubMed ID: 18771430
[TBL] [Abstract][Full Text] [Related]
14. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.
Solomon RJ; Natarajan MK; Doucet S; Sharma SK; Staniloae CS; Katholi RE; Gelormini JL; Labinaz M; Moreyra AE;
Circulation; 2007 Jun; 115(25):3189-96. PubMed ID: 17562951
[TBL] [Abstract][Full Text] [Related]
15. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention.
Jabara R; Gadesam RR; Pendyala LK; Knopf WD; Chronos N; Chen JP; Viel K; King SB; Manoukian SV
Am J Cardiol; 2009 Jun; 103(12):1657-62. PubMed ID: 19539072
[TBL] [Abstract][Full Text] [Related]
16. Risk scoring system for prediction of contrast-induced nephropathy in patients with pre-existing renal impairment undergoing percutaneous coronary intervention.
Chong E; Shen L; Poh KK; Tan HC
Singapore Med J; 2012 Mar; 53(3):164-9. PubMed ID: 22434288
[TBL] [Abstract][Full Text] [Related]
17. Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention.
Wessely R; Koppara T; Bradaric C; Vorpahl M; Braun S; Schulz S; Mehilli J; Schömig A; Kastrati A;
Circ Cardiovasc Interv; 2009 Oct; 2(5):430-7. PubMed ID: 20031753
[TBL] [Abstract][Full Text] [Related]
18. Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography.
Hardiek KJ; Katholi RE; Robbs RS; Katholi CE
J Diabetes Complications; 2008; 22(3):171-7. PubMed ID: 18413220
[TBL] [Abstract][Full Text] [Related]
19. Brain natriuretic peptide for prevention of contrast-induced nephropathy after percutaneous coronary intervention or coronary angiography.
Liu JM; Xie YN; Gao ZH; Zu XG; Li YJ; Hao YM; Chang L
Can J Cardiol; 2014 Dec; 30(12):1607-12. PubMed ID: 25418218
[TBL] [Abstract][Full Text] [Related]
20. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
